首页> 外文OA文献 >PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES

【2h】

PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES

机译：PCN56 NAB-PACLITAXEL或DOCETAXEL;作为常规帕拉他赛治疗转移性乳腺癌（MBC）的替代品：五个欧洲国家的成本效用分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Dranitsaris G; Lidgren M; Lundkvist J; Coleman R;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK) [J] . G.Dranitsaris, M.Lidgren, J.Lundkvist, European Journal of Cancer Supplements . 2008,第7期

机译：纳布紫杉醇或多西紫杉醇;作为传统紫杉醇治疗转移性乳腺癌（MBC）的替代品：英国（UK）的成本效用分析
2. Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK) [J] . G.Dranitsaris, M.Lidgren, J.Lundkvist, European Journal of Cancer Supplements . 2008,第7期

机译：纳布紫杉醇或多西紫杉醇;作为传统紫杉醇治疗转移性乳腺癌（MBC）的替代品：英国（UK）的成本效用分析
3. Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective [J] . George Dranitsaris, Bo Yu, Jennifer King, ClinicoEconomics and Outcomes Research . 2015,第2期

机译：纳布紫杉醇，多西紫杉醇或溶剂型紫杉醇在转移性乳腺癌中的应用：从中国卫生保健角度的成本-效用分析
4. IG-001—A non-biologic micellar paclitaxel formulation for the treatment of metastatic Breast cancer [C] . Motamed Kouros, Hwang Larn, Hsiao Chao, IEEE International Conference on Nano/Molecular Medicine and Engineering . 2013

机译：IG-001—用于治疗转移性乳腺癌的非生物胶束紫杉醇制剂
5. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
6. Nab-paclitaxel docetaxel or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective [O] . George Dranitsaris, Bo Yu, Jennifer King, 2015

机译：纳布紫杉醇多西紫杉醇或溶剂型紫杉醇治疗转移性乳腺癌：从中国医疗保健角度的成本-效用分析
7. PCN161 Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Based Paclitaxel in Metastatic Breast Cancer (Mbc): A Cost Utility Analysis from a Chinese Health Care Perspective [O] . Dranitsaris G., Yu B., Qing Z., 2014

机译：PCN161 Nab-紫杉醇或多西紫杉醇替代基于溶剂的紫杉醇在转移性乳腺癌（Mbc）中的应用：从中国卫生保健角度的成本效用分析

PCN56 NAB-PACLITAXEL OR DOCETAXEL; AS ALTERNATIVES TO CONVENTIONAL PACLITAXEL FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC): A COST UTILITY ANALYSIS IN FIVE EUROPEAN COUNTRIES

著录项

引文网络

相似文献

相关主题

期刊订阅